Cara Therapeutics Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Cara Therapeutics (CARA) Tops Q2 EPS by 18c
August 8, 2022 4:30 PM EDTCara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.08), $0.18 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $23 million versus the consensus estimate of $21.11 million.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
... More


